News

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...
Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...
The effectiveness of primary androgen-deprivation therapy (PADT) for clinically localized prostate cancer has been found lacking. A retrospective cohort study of more than 15,000 men newly ...
A mainstay of prostate cancer treatment at all stages is a type of hormone therapy called androgen deprivation therapy (ADT). And, newer hormone therapies and combinations with chemotherapy can ...
Hormone therapy for prostate cancer is aimed at reducing or eliminating the amount of testosterone in your body to slow or stop prostate cancer cells from growing and multiplying.
Androgen deprivation (AD) therapy for prostate cancer is being used in an increasingly wide range of settings, such as advanced disease, loco-regional disease, as an adjunct to surgery or ...
Background: Androgen deprivation therapy (ADT) has been associated with cardiovascular risk in prostate cancer patients. Thus, we performed a systematic review and meta-analysis to assess the ...
Time to Benefit of Androgen Deprivation Therapy in Patients With Localized Prostate Cancer Undergoing Radiotherapy. JCO Precis Oncol 9 , e2400605 (2025). DOI: 10.1200/PO-24-00605 ...
Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be ...
Demissei BG, Ko K, Huang A, et al. Social determinants of health mediate racial disparities in cardiovascular disease in men with prostate cancer. J Am Coll Cardiol CardioOnc. 2024;6(3):390-401 ...
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised ...